Rastilav Bahleda

2.2k total citations
66 papers, 1.2k citations indexed

About

Rastilav Bahleda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Rastilav Bahleda has authored 66 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 18 papers in Molecular Biology. Recurrent topics in Rastilav Bahleda's work include Cancer Immunotherapy and Biomarkers (13 papers), Cancer Genomics and Diagnostics (10 papers) and Lung Cancer Treatments and Mutations (9 papers). Rastilav Bahleda is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Cancer Genomics and Diagnostics (10 papers) and Lung Cancer Treatments and Mutations (9 papers). Rastilav Bahleda collaborates with scholars based in France, United States and Spain. Rastilav Bahleda's co-authors include Jean‐Charles Soria, Antoine Hollebecque, Christophe Massard, Andréa Varga, Hassan Izzedine, Jean Charles Soria, Anas Gazzah, Bernard Escudier, Dil Sahali and A Baumelou and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Rastilav Bahleda

62 papers receiving 1.2k citations

Peers

Rastilav Bahleda

ONCOL

PRM

IMMUN

Philipp Ivanyi Germany

Elena De Mattia Italy

Yong Mee Cho South Korea

Lone H. Ottesen United States

Yan Qin China

Ramona Dadu United States

Oezlem Anak United States

Jennifer Arrondeau France

Melanie Poulin-Costello Canada

Cletus A. Arciero United States

Philipp Ivanyi Germany

Rastilav Bahleda

440 ×0.8

ONCOL

249 ×0.5

468 ×1.1

PRM

146 ×0.9

141 ×0.9

IMMUN

Citations per year, relative to Rastilav Bahleda Rastilav Bahleda (= 1×) peers Philipp Ivanyi

Countries citing papers authored by Rastilav Bahleda

Since Specialization

Citations

This map shows the geographic impact of Rastilav Bahleda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rastilav Bahleda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rastilav Bahleda more than expected).

Fields of papers citing papers by Rastilav Bahleda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rastilav Bahleda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rastilav Bahleda. The network helps show where Rastilav Bahleda may publish in the future.

Co-authorship network of co-authors of Rastilav Bahleda

This figure shows the co-authorship network connecting the top 25 collaborators of Rastilav Bahleda. A scholar is included among the top collaborators of Rastilav Bahleda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rastilav Bahleda. Rastilav Bahleda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bahleda, Rastilav, Elena Lorenzo, Ramón Yarza, et al.. (2025). 1566P Phase I study of intratumoral administration of JNJ-87704916, an oncolytic virus, as monotherapy and in combination with cetrelimab in advanced solid tumors. Annals of Oncology. 36. S871–S871.

Assi, Tarek, Carine Ngo, Matthieu Faron, et al.. (2025). Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis. Cancer Treatment Reviews. 134. 102904–102904. 1 indexed citations

Smolenschi, Cristina, Antoine Hollebecque, Damien Vasseur, et al.. (2023). 1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials. Annals of Oncology. 34. S913–S914. 1 indexed citations

Martín-Romano, Patricia, Léo Colmet‐Daage, Daphné Morel, et al.. (2022). Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials. European Journal of Cancer. 173. 133–145. 1 indexed citations

Cousin, Sophie, Carine Bellera, Rastilav Bahleda, et al.. (2022). 1494P Regomune - a phase II study of regorafenib + avelumab in solid tumors: Results of the soft tissue sarcoma (STS) cohort. Annals of Oncology. 33. S1230–S1230. 3 indexed citations

Nassif, Elise F., Édouard Auclin, Rastilav Bahleda, et al.. (2021). TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials. Cancers. 13(13). 3362–3362. 7 indexed citations

Wainberg, Zev A., Ignacio Matos, Jean‐Pierre Delord, et al.. (2021). LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer. Annals of Oncology. 32. S227–S228. 15 indexed citations

Schöffski, Patrick, Rastilav Bahleda, Andrew J. Wagner, et al.. (2021). 154P Results of an open-label, phase Ia/Ib study of olaratumab plus pembrolizumab in patients with unresectable, locally advanced or metastatic soft tissue sarcoma. Annals of Oncology. 32. S1447–S1447. 1 indexed citations

Gauci, Marie-Léa, Émilie Lanoy, Stéphane Champiat, et al.. (2018). Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research. 25(3). 946–956. 106 indexed citations

10.

Aspeslagh, Sandrine, Eduardo Castañón, Valérie Dyevre, et al.. (2018). Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. European Journal of Cancer. 95. 68–74. 20 indexed citations

11.

Aspeslagh, Sandrine, Kunwar Shailubhai, Rastilav Bahleda, et al.. (2017). Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 79(6). 1257–1265. 27 indexed citations

12.

Goyal, Lipika, Hendrik-Tobias Arkenau, Ben Tran, et al.. (2017). Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma. Annals of Oncology. 28. iii145–iii145. 18 indexed citations

13.

Calvo, Emiliano, Jean‐Charles Soria, Wen Wee, et al.. (2016). A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clinical Cancer Research. 23(5). 1177–1185. 29 indexed citations

14.

Aspeslagh, Sandrine, Mark N. Stein, Rastilav Bahleda, et al.. (2016). Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. Anti-Cancer Drugs. 28(3). 341–349. 11 indexed citations

15.

Jung, Joonil, Joon Sang Lee, Mark A. Dickson, et al.. (2016). TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. Nature Communications. 7(1). 12609–12609. 78 indexed citations

16.

Kossaï, Myriam, Boris Duchemann, C. Boutros, et al.. (2015). Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer. 89(3). 306–310. 8 indexed citations

17.

Deutsch, Éric, C. Le Péchoux, Laurence Faivre, et al.. (2015). Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. Annals of Oncology. 26(6). 1223–1229. 42 indexed citations

18.

Soria, J.C., Filippo de Braud, Rastilav Bahleda, et al.. (2014). Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Annals of Oncology. 25(11). 2244–2251. 147 indexed citations

19.

Martinez‐García, Maria, Udai Banerji, Joan Albanell, et al.. (2012). First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. Clinical Cancer Research. 18(17). 4806–4819. 122 indexed citations

20.

Zoubir, Mustapha, Caroline Flament, Abdelaziz Gdoura, et al.. (2011). An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpes viridae. Cell Cycle. 10(1). 118–126. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact